Nov 25 (Reuters) - ChemoCentryx Inc:
* CHEMOCENTRYX AND VFMCRP ANNOUNCE POSITIVE TOPLINE DATA FROM PIVOTAL PHASE III ADVOCATE TRIAL DEMONSTRATING AVACOPAN’S SUPERIORITY OVER STANDARD OF CARE IN ANCA-ASSOCIATED VASCULITIS
* CHEMOCENTRYX INC - TRIAL ACHIEVED BOTH PRIMARY ENDPOINTS OF CLINICAL REMISSION AT WEEKS 26 AND 52
* CHEMOCENTRYX INC - TRIAL DEMONSTRATED STATISTICAL SUPERIORITY OF AVACOPAN OVER STANDARD OF CARE (SOC) AT 52 WEEKS
* CHEMOCENTRYX INC - AVACOPAN SIGNIFICANTLY REDUCED GLUCOCORTICOID TOXICITY
* CHEMOCENTRYX INC - AVACOPAN SIGNIFICANTLY IMPROVED KIDNEY FUNCTION COMPARED TO GLUCOCORTICOID-CONTAINING SOC
* CHEMOCENTRYX INC - PLAN TO MAKE REGULATORY SUBMISSIONS OF AVACOPAN FOR FULL MARKETING APPROVAL TO BOTH EMA AND FDA IN 2020 Source text for Eikon: Further company coverage: